IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Adherence and Risk Behaviour in Patients With HIV Infection Receiving Antiretroviral Therapy (ARB)
This study has been completed.
Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration
Collaborator:
Kirby Institute
Information provided by:
The HIV Netherlands Australia Thailand Research Collaboration
ClinicalTrials.gov Identifier:
NCT00511056
First received: August 2, 2007
Last updated: July 7, 2011
Last verified: July 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Study Hypothesis: Do certain risk behaviours impact/predict levels of HIV antiretroviral adherence?
Objectives:
- To assess risk behavior in HIV-positive individuals receiving highly active antiretroviral therapy.(HAART)
- To assess levels of adherence in the same subjects at the same time point
- To determine if there is a correlation between HAART adherence and risk behaviour
| Condition |
|---|
| HIV Infections |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Cross-Sectional |
| Official Title: | Adherence and Risk Behaviour in Patients With HIV Infection Receiving Antiretroviral Therapy |
Resource links provided by NLM:
Further study details as provided by The HIV Netherlands Australia Thailand Research Collaboration:
Primary Outcome Measures:
- The relationship between sexual risk behavior and adherence to HIV medications and how do these behaviors relate to patient beliefs about HIV transmission. [ Time Frame: 2 Years ]
Biospecimen Retention: Samples With DNA
Blood samples required to provide Viral Load data and CD4 cell count
| Enrollment: | 700 |
| Study Start Date: | September 2007 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | January 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
HIVNAT 006
HIVNAT 006 is a long term follow up cohort. The primary objective of this study is to collect and evaluate the long-term clinical outcomes of HIV infected patients have participated in HIV-NAT studies. These subjects will be used to test our hypothesis.
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
Approximately 500 subjects were surveyed from the HIVNAT 006 long term follow up cohort. A sample size as large as this is likely to yield accurate results as to the true relationship between sexual risk behavior and adherence to HIV medications.
Criteria
Inclusion Criteria:
- Age ≥ 18 years
- HIV seropositive.
- On continuous HAART for at least 6 months
- Signed written informed consent
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00511056
Please refer to this study by its ClinicalTrials.gov identifier: NCT00511056
Locations
| Thailand | |
| HIV-NAT, Thai Red Cross AIDS Research Centre | |
| Bangkok, Thailand, 10330 | |
Sponsors and Collaborators
The HIV Netherlands Australia Thailand Research Collaboration
Kirby Institute
Investigators
| Principal Investigator: | Kiat Ruxrungtham, M.D., M.Sc. | HIVNAT |
More Information
Additional Information:
Publications:
Honeybrook AL. Adherence and Risk Behaviour in Patients With HIV Recieving antiretroviral therapy. XVII International AIDS Conference 2008. Mexico City, Mexico.
| Responsible Party: | Dr Kiat Ruxrungtham, The HIV Netherlands Australia Thailand Research Collaboration |
| ClinicalTrials.gov Identifier: | NCT00511056 History of Changes |
| Other Study ID Numbers: |
HIV-NAT Amendment II to 006 |
| Study First Received: | August 2, 2007 |
| Last Updated: | July 7, 2011 |
Keywords provided by The HIV Netherlands Australia Thailand Research Collaboration:
|
HIV Adherence Compliance Highly Active Antiretroviral Therapy (HAART) ARV |
ART Sexual Risk Behavior Unsafe Transmission |
Additional relevant MeSH terms:
|
Infection Communicable Diseases HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections |
Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
ClinicalTrials.gov processed this record on June 23, 2017